NTRK2

Oncogene
BDNF/NT-3 growth factors receptor UniProt accession Q16620

Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:15494731, PubMed:7574684).

Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:15494731). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth.

Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation.

PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia

Source: UniProt

Exists in a dynamic equilibrium between monomeric (low affinity) and dimeric (high affinity) structures. Interacts (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 phosphorylation and activation. Interacts (phosphorylated upon activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 phosphorylation and activation.

Interacts with SH2B1 and SH2B2. Interacts with NGFR; may regulate the ligand specificity of the receptor (By similarity). Interacts with SORCS2; this interaction is important for normal targeting to post-synaptic densities in response to high-frequency stimulation (By similarity).

Interacts (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts (phosphorylated upon ligand-binding) with FRS2; activates the MAPK signaling pathway (PubMed:10092678).

Interacts with APPL1 (By similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with SORL1; this interaction facilitates NTRK2 trafficking between synaptic plasma membranes, postsynaptic densities and cell soma, hence positively regulates BDNF signaling (By similarity).

Interacts with SLITRK2 (PubMed:35840571)

Source: UniProt
Cell membrane — Single-pass type I membrane protein, Endosome membrane — Single-pass type I membrane protein, Early endosome membrane, Cell projection, axon, Cell projection, dendrite, Cytoplasm, perinuclear region, Postsynaptic density
Source: UniProt

Isoform TrkB is expressed in the central and peripheral nervous system. In the central nervous system (CNS), expression is observed in the cerebral cortex, hippocampus, thalamus, choroid plexus, granular layer of the cerebellum, brain stem, and spinal cord. In the peripheral nervous system, it is expressed in many cranial ganglia, the ophthalmic nerve, the vestibular system, multiple facial structures, the submaxillary glands, and dorsal root ganglia.

Isoform TrkB-T1 is mainly expressed in the brain but also detected in other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc is predominantly expressed in the brain

Source: UniProt
  • Developmental and epileptic encephalopathy 58 (DEE58)

    A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE58 is an autosomal dominant condition characterized by onset of refractory seizures in the first days or months of life.

  • Obesity, hyperphagia, and developmental delay (OBHD)

    A disorder characterized by early-onset obesity, hyperphagia, and severe developmental delay in motor function, speech, and language.

Source: UniProt
  • PIP3 activates AKT signaling
  • NGF-independant TRKA activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • BDNF activates NTRK2 (TRKB) signaling
  • NTF3 activates NTRK2 (TRKB) signaling
  • NTF4 activates NTRK2 (TRKB) signaling
  • Activated NTRK2 signals through RAS
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PI3K
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FYN
  • NTRK2 activates RAC1
  • Activated NTRK2 signals through CDK5
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 0.57%
Lung Adenocarcinoma 3.05%
Lung Small Cell Carcinoma 3.26%
Lung Squamous Cell Carcinoma 1.90%
Oesophagus Squamous Cell Carcinoma 0.35%
Pancreas Ductal Carcinoma 1.38%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to NTRK2, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 15

NCT ID Condition Brief Title Phase Status
NCT02637687 Solid Tumors Harboring NTRK Fusion A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children PHASE1, PHASE2 ACTIVE_NOT_RECRUITING
NCT03375437 Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. NA ACTIVE_NOT_RECRUITING
NCT04557813 NTRK Family Gene Mutation Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion N/A COMPLETED
NCT02097810 Locally Advanced Solid Tumors, Metastatic Solid Tumors Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. PHASE1 COMPLETED
NCT02576431 Solid Tumors Harboring NTRK Fusion A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors PHASE2 COMPLETED
NCT02920996 Carcinoma, Non-Small-Cell Lung, Solid Tumor Merestinib In Non-Small Cell Lung Cancer And Solid Tumors PHASE2 TERMINATED
NCT03215511 Solid Tumors Harboring NTRK Fusion A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer PHASE1 COMPLETED
NCT02650401 Solid Tumors, CNS Tumors Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options PHASE1, PHASE2 ACTIVE_NOT_RECRUITING
NCT02568267 Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) PHASE2 ACTIVE_NOT_RECRUITING
NCT03206931 Solid Tumors Harboring NTRK Fusion Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion N/A NO_LONGER_AVAILABLE